Prospective evaluation of return to work, health-related quality of life and psychosocial distress after radical cystectomy: 1-year follow-up in 230 employed German bladder cancer patients.
Bladder cancer
Psychosocial distress
Quality of life
Radical cystectomy
Return to work
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
11
06
2023
accepted:
03
08
2023
medline:
23
10
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
ppublish
Résumé
To evaluate return to work (RTW), health-related quality of life (HRQoL) and psychosocial distress (PD) after radical cystectomy (RC) and creation of an ileal conduit (IC) or an orthotopic ileal neobladder (NB) for bladder cancer. The study relied on prospectively collected data for 842 patients, who underwent 3 weeks of inpatient rehabilitation (IR) after surgery between April 2018 and December 2019. HRQoL (EORTC QLQ-C30) and PD (Questionnaire on Stress in Cancer Patients [QSC-R10]) were evaluated at the beginning (T1) and end (T2) of IR as well as both 6 (T3) and 12 months after surgery (T4). Regression analyses were performed to identify predictors of HRQoL and RTW, respectively. Two hundred thirty patients (IC n = 51, NB n = 179) were employed before surgery (27.3%). HRQoL improved steadily, while high PD was present in 51.0% of patients at T4. RTW rate was 86.8 and 80.6% at T3 and T4, respectively. Linear regression analysis identified RTW as the only predictor for better HRQoL at T4 (OR [odds ratio] 12.823, 95% CI [confidence interval] 2.927-22.720, p = 0.012). Multivariate regression analysis identified age ≤ 59 years (OR 7.842; 95% CI 2.495-24.645; p < 0.001) as an independent positive predictor and lymph node metastasis (OR 0.220; 95% CI 0.054-0.893; p = 0.034) as an independent negative predictor of RTW at T4. Global HRQoL improved steadily during the follow-up and RTW rates are high. However, patients often reported high PD, reflecting a need for additional psychosocial support within aftercare.
Identifiants
pubmed: 37702752
doi: 10.1007/s00345-023-04570-1
pii: 10.1007/s00345-023-04570-1
pmc: PMC10581950
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2707-2713Informations de copyright
© 2023. The Author(s).
Références
J Clin Oncol. 2012 Oct 20;30(30):3675-86
pubmed: 23008308
Eur J Cancer Care (Engl). 2007 Jan;16(1):17-25
pubmed: 17227349
Eur Urol. 2013 Jan;63(1):67-80
pubmed: 22995974
Psychooncology. 2011 Mar;20(3):287-93
pubmed: 20669340
Surg Oncol. 2016 Sep;25(3):281-97
pubmed: 27566035
Curr Neurol Neurosci Rep. 2012 Jun;12(3):267-75
pubmed: 22453825
J Urol. 2017 Sep;198(3):552-559
pubmed: 28456635
Eur Urol Focus. 2022 Mar;8(2):465-471
pubmed: 33712389
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
Dtsch Arztebl Int. 2012 Oct;109(42):702-8
pubmed: 23264814
PLoS One. 2013 Sep 10;8(9):e74149
pubmed: 24058523
Psychooncology. 2019 Dec;28(12):2429-2431
pubmed: 31595616
Int J Environ Res Public Health. 2022 Apr 22;19(9):
pubmed: 35564514
J Cancer Surviv. 2007 Jun;1(2):129-36
pubmed: 18648953
Support Care Cancer. 2006 May;14(5):427-35
pubmed: 16402234
Eur J Cancer. 2004 Nov;40(16):2488-93
pubmed: 15519524
JAMA Netw Open. 2022 Feb 1;5(2):e2148329
pubmed: 35171260
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
JAMA. 2009 Feb 18;301(7):753-62
pubmed: 19224752
Health Qual Life Outcomes. 2023 May 11;21(1):44
pubmed: 37170308
Crit Rev Oncol Hematol. 2011 Feb;77(2):109-30
pubmed: 20117019
Cancers (Basel). 2021 Oct 14;13(20):
pubmed: 34680310
Gesundheitswesen. 1999 Dec;61 Spec No:S178-83
pubmed: 10726418